Other
CN
EU
USA
Description: Conivaptan HCl (also known as YM 087, trade name Vaprisol) is a novel, potent, orally bioavailable, and non-peptide vasopressin V1A and V2 receptor antagonist with Ki values of 0.48 and 3.04 nM for rat liver V1A receptor and rat kidney V2 receptor respectively. It is used in the treatment of euvolemic and hypervolemic hyponatremia. It was approved in 2004 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH), and there is some evidence it may be effective in heart failure. Conivaptan inhibits two of the three subtypes of the vasopressin receptor (V1a and V2). Effectively, it causes iatrogenic nephrogenic diabetes insipidus.
References: Eur J Pharmacol. 2005 Jan 10;507(1-3):145-51; J Hepatol. 2003 Jun;38(6):755-61.
Related CAS#: 210101-16-9(free base)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
In vitro activity: Conivaptan (hydrochloride) is a non-peptide antagonist of vasopressin receptor, with Ki values of 0.48 and 3.04 nM for rat liver V1A receptor and rat kidney V2 receptor respectively.
Purity ≥98%
COA
MSDS